抗TNF抗体阴性且无抗药抗体者换用第二种抗TNF时加用硫唑嘌呤的前瞻性随机试验
结果显示联合治疗组临床失败和药代动力学不良的发生率显著低于单药组,24个月无临床失败生存率分别为77%对22%。结论认为此类患者换用第二种抗TNF时应联合硫唑嘌呤。
要点
- 免疫介导性抗TNF失应答的IBD患者换药时,联合硫唑嘌呤优于单用第二种抗TNF。
- 联合治疗组24个月无临床失败生存率为77%,单药组为22%。
- 联合治疗组24个月无药代动力学不良生存率为78%,单药组为22%。
核心结论
- 对于第一种优化抗TNF单药治疗出现免疫介导性失应答的IBD患者,换用第二种抗TNF时应联合硫唑嘌呤。
研究设计与样本
- 第二种抗TNF为阿达木单抗40例、英夫利西单抗50例,随访2年比较临床失败和药代动力学失败时间。
主要发现
- 单药组临床失败和药代动力学不良发生率均高于联合治疗组(p<0.001),临床失败中位时间分别为18个月和>24个月。
- 24个月无临床失败生存率单药组22%对联合治疗组77%(p<0.001)。
- 24个月无药代动力学不良生存率单药组22%对联合治疗组78%(p<0.001)。
- 仅联合治疗与换用抗TNF后的有利结局相关。
关键数值与推荐
- 克罗恩病临床失败定义为Harvey-Bradshaw指数≥5且粪钙卫蛋白>250 µg/g粪便。
- 溃疡性结肠炎临床失败定义为Mayo评分>5且内镜子评分>1,或出现需停药的 adverse events。
- 药代动力学不良定义为出现抗TNF谷浓度不可测且高抗体(药物敏感检测法)或出现抗体(药物耐受检测法)。
临床怎么用
- 对免疫介导性失应答且抗TNF谷浓度不可测、抗药抗体阴性的IBD患者,换用第二种抗TNF时应联合硫唑嘌呤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with IBD experiencing an immune-mediated loss of response (LOR) to antitumour necrosis factor (anti-TNF), algorithms recommend a switch of anti-TNF without immunosuppressive drug. The aim of our study was to compare in these patients two strategies: either switch to a second anti-TNF alone or with addition of azathioprine (AZA). After randomisation outcomes (time to clinical and pharmacokinetic failure) were compared between the two groups during a 2-year follow-up period. DESIGN: Consecutive IBD patients in immune-mediated LOR to a first optimised anti-TNF given in monotherapy were randomised to receive either AZA or nothing with induction by a second anti-TNF in both arms. Clinical failure was defined for Crohn's disease (CD) as a Harvey-Bradshaw index ≥5 associated with a faecal calprotectin level >250 µg/g stool and for UC as a Mayo score >5 with endoscopic subscore >1 or as the occurrence of adverse events requiring to stop treatment. Unfavourable pharmacokinetics of the second anti-TNF were defined by the appearance of undetectable trough levels of anti-TNF with high antibodies (drug-sensitive assay) or by that of antibodies (drug-tolerant assay). RESULTS: Ninety patients (48 CDs) were included, and 45 of them received AZA after randomisation. The second anti-TNF was adalimumab or infliximab in 40 and 50 patients, respectively. Rates of clinical failure and occurrence of unfavourable pharmacokinetics were higher in monotherapy compared with combination therapy (p<0.001; median time of clinical failure since randomisation 18 vs >24 months). At 24 months, survival rates without clinical failure and without appearance of unfavourable pharmacokinetics were respectively 22 versus 77% and 22% versus 78% (p<0.001 for both) in monotherapy versus combination therapy. Only the use of combination therapy was associated with favourable outcomes after anti-TNF switch. CONCLUSION: In case of immune-mediated LOR to a first anti-TNF, AZA should be associated with the second anti-TNF. TRIAL REGISTRATION NUMBER: 03580876.
引用
- Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut. 2020. PMID: 31980448. doi:10.1136/gutjnl-2019-319758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。